BR112017005760A2 - conjugados e reagentes de conjugação - Google Patents
conjugados e reagentes de conjugaçãoInfo
- Publication number
- BR112017005760A2 BR112017005760A2 BR112017005760A BR112017005760A BR112017005760A2 BR 112017005760 A2 BR112017005760 A2 BR 112017005760A2 BR 112017005760 A BR112017005760 A BR 112017005760A BR 112017005760 A BR112017005760 A BR 112017005760A BR 112017005760 A2 BR112017005760 A2 BR 112017005760A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- peptide
- group
- polyethylene glycol
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
a presente invenção refere-se a um conjugado de uma proteína ou peptídeo com um agente terapêutico, de diagnóstico ou de rotulagem, o referido conjugado contendo uma porção de ligação de proteína ou peptídeo e uma porção de polietileno glicol; em que a referida porção de ligação de proteína ou peptídeo tem a fórmula geral: em que pr representa referida proteína ou peptídeo, cada nu representa um nucleófilo presente em ou ligado à proteína ou peptídeo, cada de a e b independentemente representa uma cadeia de c1-4alquileno ou alquenileno, e w representa um grupo de remoção de elétron ou um grupo obtido por redução de um grupo de remoção de elétron; e em que referida porção de polietileno glicol é ou inclui uma cadeia de polietileno glicol pendente que tem um grupo de extremidade terminal de fórmula ch2ch2or em que r representa um átomo de hidrogênio, um grupo alquila, ou um grupo arila opcionalmente substituído. também reivindicados são um método para preparar um tal conjugado, e novos reagentes úteis naquele método.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1418984.9A GB2531715A (en) | 2014-10-24 | 2014-10-24 | Novel drug conjugates |
GBGB1418986.4A GB201418986D0 (en) | 2014-10-24 | 2014-10-24 | Novel conjugates and novel conjugating reagents |
GBGB1418989.8A GB201418989D0 (en) | 2014-10-24 | 2014-10-24 | Novel conjugation process and reagents |
PCT/GB2015/052953 WO2016063006A1 (en) | 2014-10-24 | 2015-10-08 | Conjugates and conjugating reagents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017005760A2 true BR112017005760A2 (pt) | 2017-12-12 |
Family
ID=54337308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017005760A BR112017005760A2 (pt) | 2014-10-24 | 2015-10-08 | conjugados e reagentes de conjugação |
Country Status (15)
Country | Link |
---|---|
US (2) | US20170290925A1 (pt) |
EP (1) | EP3220956B1 (pt) |
JP (1) | JP6612860B2 (pt) |
KR (1) | KR102513926B1 (pt) |
CN (1) | CN107073131B (pt) |
AU (1) | AU2015334717B2 (pt) |
BR (1) | BR112017005760A2 (pt) |
CA (1) | CA2963043A1 (pt) |
ES (1) | ES2960741T3 (pt) |
IL (1) | IL250644B (pt) |
MX (1) | MX2017005199A (pt) |
RU (1) | RU2017108448A (pt) |
SG (1) | SG11201701342XA (pt) |
WO (1) | WO2016063006A1 (pt) |
ZA (1) | ZA201701337B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10098960B2 (en) | 2015-04-03 | 2018-10-16 | Ucl Business Plc | Polymer conjugate |
EP3402825A1 (en) | 2016-01-12 | 2018-11-21 | Crescendo Biologics Limited | Molecules that bind prostate specific membrane antigen (psma) |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
EP3442595A1 (en) | 2016-04-14 | 2019-02-20 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring |
GB201608936D0 (en) * | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
CN109311996B (zh) | 2016-06-06 | 2023-11-28 | 阿布泽纳(英国)有限公司 | 抗体、其用途及其缀合物 |
GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
GB201615725D0 (en) | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
JP6990355B2 (ja) | 2017-03-30 | 2022-01-12 | 日油株式会社 | ヘテロ二官能性単分散ポリエチレングリコール及びそれを用いた複合体 |
GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
CA3093645A1 (en) | 2018-03-13 | 2019-09-19 | Nof Corporation | Heterobifunctional compound having monodispersed polyethylene glycol in main chain and side chain |
EP3789401A1 (en) | 2019-09-03 | 2021-03-10 | Gamamabs Pharma | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |
GB2594753B (en) | 2020-05-27 | 2022-05-18 | Spirea Ltd | Antibody-drug conjugates |
WO2023047090A1 (en) | 2021-09-21 | 2023-03-30 | Spirea Limited | Antibody-drug conjugates |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
EP1061954B1 (en) * | 1998-03-12 | 2004-06-09 | Nektar Therapeutics Al, Corporation | Poly(ethylene glycol) derivatives with proximal reactive groups |
KR100511749B1 (ko) * | 2001-11-06 | 2005-09-02 | 선바이오(주) | 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체 |
DK1725249T3 (en) * | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
US8158590B2 (en) * | 2005-08-05 | 2012-04-17 | Syntarga B.V. | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation |
US20070141134A1 (en) * | 2005-12-16 | 2007-06-21 | Kosak Matthew K | Shielded micelles for polynucleotide delivery |
EP2073820A4 (en) * | 2006-09-15 | 2014-07-16 | Belrose Pharma Inc | TARGETED POLYMER PRODRUGS WITH MULTIFUNCTIONAL CONNECTORS |
EP2118150B1 (en) * | 2007-02-14 | 2015-09-23 | Biocompatibles UK Limited | Derivatisation of biological molecules |
GB0922354D0 (en) * | 2009-12-21 | 2010-02-03 | Polytherics Ltd | Novel polymer conjugates |
DK2678037T3 (en) * | 2011-02-25 | 2015-03-09 | Lonza Ag | Branched linker for protein pharmaceutical conjugates |
CN104906592B (zh) * | 2011-02-25 | 2017-11-03 | 广州南沙龙沙有限公司 | 用于蛋白质药物偶联物的支链联接体 |
GB201210770D0 (en) * | 2012-06-18 | 2012-08-01 | Polytherics Ltd | Novel conjugation reagents |
US9650331B2 (en) * | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
KR20150023027A (ko) * | 2012-06-19 | 2015-03-04 | 폴리테릭스 리미티드 | 항체 접합체의 제조를 위한 신규한 공정 및 신규한 항체 접합체 |
NO2789793T3 (pt) * | 2012-10-24 | 2018-01-27 | ||
MY169147A (en) * | 2012-10-24 | 2019-02-18 | Polytherics Ltd | Drug-protein conjugates |
PT3057585T (pt) * | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
-
2015
- 2015-10-08 WO PCT/GB2015/052953 patent/WO2016063006A1/en active Application Filing
- 2015-10-08 MX MX2017005199A patent/MX2017005199A/es unknown
- 2015-10-08 EP EP15782051.5A patent/EP3220956B1/en active Active
- 2015-10-08 RU RU2017108448A patent/RU2017108448A/ru unknown
- 2015-10-08 SG SG11201701342XA patent/SG11201701342XA/en unknown
- 2015-10-08 US US15/517,969 patent/US20170290925A1/en not_active Abandoned
- 2015-10-08 BR BR112017005760A patent/BR112017005760A2/pt not_active Application Discontinuation
- 2015-10-08 JP JP2017519672A patent/JP6612860B2/ja active Active
- 2015-10-08 ES ES15782051T patent/ES2960741T3/es active Active
- 2015-10-08 KR KR1020177010432A patent/KR102513926B1/ko active IP Right Grant
- 2015-10-08 CA CA2963043A patent/CA2963043A1/en not_active Abandoned
- 2015-10-08 AU AU2015334717A patent/AU2015334717B2/en active Active
- 2015-10-08 CN CN201580057559.0A patent/CN107073131B/zh active Active
-
2017
- 2017-02-16 IL IL250644A patent/IL250644B/en active IP Right Grant
- 2017-02-22 ZA ZA2017/01337A patent/ZA201701337B/en unknown
-
2020
- 2020-03-03 US US16/807,298 patent/US20200268885A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2017108448A (ru) | 2018-11-27 |
ES2960741T3 (es) | 2024-03-06 |
SG11201701342XA (en) | 2017-03-30 |
CN107073131A (zh) | 2017-08-18 |
US20170290925A1 (en) | 2017-10-12 |
EP3220956A1 (en) | 2017-09-27 |
IL250644A0 (en) | 2017-06-29 |
IL250644B (en) | 2020-10-29 |
CA2963043A1 (en) | 2016-04-28 |
KR102513926B1 (ko) | 2023-03-23 |
AU2015334717A1 (en) | 2017-04-13 |
EP3220956B1 (en) | 2023-08-09 |
ZA201701337B (en) | 2018-05-30 |
WO2016063006A1 (en) | 2016-04-28 |
JP6612860B2 (ja) | 2019-11-27 |
CN107073131B (zh) | 2021-05-25 |
US20200268885A1 (en) | 2020-08-27 |
AU2015334717B2 (en) | 2021-02-25 |
MX2017005199A (es) | 2017-07-26 |
JP2017537062A (ja) | 2017-12-14 |
KR20170075724A (ko) | 2017-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017005760A2 (pt) | conjugados e reagentes de conjugação | |
MX2023008041A (es) | Composiciones de acido nucleico-polipeptido y sus aplicaciones. | |
CY1119436T1 (el) | Σκευασμα για αντισωμα εναντι- 4 7 | |
ZA201805336B (en) | Amanitin conjugates | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
MX2020002183A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos. | |
MA52645B1 (fr) | Vaccins contre le virus respiratoire | |
BR112019005595A2 (pt) | compostos e métodos para modulação de ido e tdo, e indicações para os mesmos | |
BR112018010720A2 (pt) | agonistas do receptor de apelina e métodos de uso | |
BR112015021838A2 (pt) | amatoxina, método de síntese, composição farmacêutica | |
BR112019024747A2 (pt) | formulações de dose fixa | |
PH12015502180A1 (en) | Wt1-antigen peptide conjugate vaccine | |
PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
CL2016003048A1 (es) | Analogos de panonina minimas sintesis y uso de los mismos. | |
BRPI1010620B8 (pt) | métodos de conjugação | |
BR112017012482A2 (pt) | copolímero estático, composição, uso de um copolímero, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção do copolímero. | |
MX2020001472A (es) | Nuevo metodo para sintetizar amanitinas. | |
CY1122441T1 (el) | Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
BR112015007238A2 (pt) | amida de ácido graxo à base de ácido 14-hidróxi-eicosanóico, como organogelificante | |
ZA202001747B (en) | Psma-targeting amanitin conjugates | |
MX2018000239A (es) | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. | |
ECSP17069696A (es) | Compuestos novedosos | |
CY1122287T1 (el) | Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ | |
MX2020008323A (es) | Composiciones farmacéuticas hipertónicas que contienen un agente quimioprotector antiplatino. | |
BR112015013675A2 (pt) | composições compreendendo vortioxetina e donepezil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61P 35/00 (2006.01) |
|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |